AMD 

Cataract & Refractive

Cornea

Gene Therapy

Glaucoma

Inflammation & Infection

Paediatrics

Retina

Articles

Media

All Videos

Eyeviews

Insights

Medical World News

Podcasts

Rapid Readouts

Viewpoints

Publications

Digital Edition

Supplements And Featured Publications

Conferences

Conference Listing 

CME/CE

Resources

ZEISS Clinical Cases

Zeiss Cataract Insights

Zeiss Cataract Digitalization

Enhancing the Patient Journey

EYLEA 8mg for nAMD and DME Treatment

Between the Lines

Subscribe

Advertise

About Us

Editorial Info

Editorial Board

Contact Us

Terms and Conditions

Privacy

Do Not Sell My Personal Information

Ophthalmology Times Europe

Facebook

LinkedIn

Spotlight

High-Frequency Deep Sclerotomy

iCare COMPASS Automated Perimeter

Clinical

Stay current on pertinent research coming out of eye care conferences across the industry. Our abbreviated video series features Key Opinion Leaders (KOLs) as they walk through poster presentations with relevant findings.

1rem

Dr. Marion Munk reviews clinical trials of high-dose aflibercept in neovascular age-related macular degeneration (AMD) and diabetic macular oedema (DMO), providing insights and discussing the clinical implications derived from these trials.

Aflibercept 8mg in Neovascular AMD and DMO: Insights from PULSAR and PHOTON Trials

Dr Arshad Khanani details the key learnings from the real-world evidence generated in the TRUCKEE and TAHOE studies following the FDA approval of faricimab.

Faricimab in the Real World

Dr Marco Zarbin presents his talk from the 2023 ASRS annual meeting, where he explores the impact of disease activity criteria on drug durability estimations in clinical trials and includes a comparative analysis across multiple clinical trials in neovascular AMD (age-related macular degeneration).

Impact of Disease Activity Criteria on Dosing Interval Assignment in Clinical Trials in nAMD

Dr Varun Chaudhary shares insights from his presentation at the 2023 ARVO annual meeting, highlighting key findings on personalized treatment interval dosing using faricimab.

Individualized Faricimab Dosing up to Every 16 Weeks Maintains Robust Anatomic and Vision Outcomes Through 2 Years in nAMD

In this Rapid Readout, Dr Jennifer Lim shares her presentation from the 2023 ARVO annual meeting, highlighting the visual and anatomic outcomes observed in clinical trials of faricimab when administered according to a personalized treatment algorithm for patients with diabetic macular edema (DME).

Durable Vision Gains and Greater Fluid Control With Extended Faricimab Dosing vs Aflibercept in Patients With DME

Dr David Almeida shares insights from his presentation at the 14th Annual Congress on Controversies in Ophthalmology (COPHy) in Lisbon, Portugal.

The TRUCKEE Study: Real-World Efficacy and Safety of Faricimab in Neovascular AMD

Anat Loewenstein, MD, MHA, discusses data from the Angiogenesis, Exudation, and Degeneration 2021 Virtual Symposium on angiopoietin-2/VEGF-A dual inhibition in the management of diabetic macular edema and exudative age-related macular degeneration.

Rapid Readout: Angiopoietin-2 (Ang2) Inhibition in the Treatment of Diabetic Macular Edema and Exudative AMD.